Revenue and Income - Rental income from the property investment segment increased to HKD 14.6 million for the six months ended June 30, 2022, compared to HKD 8.1 million in 2021, primarily due to the income generated from the Capella Building investment[16]. - Revenue from the financial investment and services segment decreased to zero for the six months ended June 30, 2022, down from HKD 1.1 million in 2021, as receivables narrowed to zero[17]. - Other income for the six months ended June 30, 2022, was HKD 0.4 million, down from HKD 2.1 million in 2021, mainly due to a decrease in commission income following the termination of the Maserati dealership[20]. - Total group revenue for the six months ended June 30, 2022, was HKD 14,560,000, compared to HKD 9,168,000 for the same period in 2021, representing a year-over-year increase of 58.8%[140][142]. - The company’s property investment segment generated revenue of HKD 14,560,000 during the interim period, while the financial investment and services segment reported a loss of HKD 170,000[140]. Profit and Loss - Gross profit decreased by HKD 4.2 million to HKD 11.5 million, with a gross profit margin increase of 52.9 percentage points to 78.8% due to the termination of the Maserati dealership business[18]. - The net loss from other gains and losses was HKD 90.9 million, compared to a net gain of HKD 14.9 million in 2021, primarily due to unrealized fair value losses on an investment in an associate[21]. - Shareholders' loss attributable to the company was HKD 109.9 million for the six months ended June 30, 2022, compared to HKD 1.1 million in 2021, primarily due to unrealized fair value losses on investments[28]. - The company reported a loss attributable to owners of the company of HKD (107,276) thousand for the six months ended June 30, 2022, compared to a profit of HKD 4,833 thousand for the same period in 2021[104]. - The company reported a loss before tax of HKD 105,339,000 for the six months ended June 30, 2022, compared to a profit before tax of HKD 9,182,000 for the same period in 2021[140][142]. Expenses and Costs - Selling and distribution costs, along with administrative expenses, totaled HKD 11.4 million, down from HKD 23.1 million in 2021, representing 78.5% of revenue[22]. - Financial costs increased to HKD 6.5 million for the period, up from HKD 5.3 million in 2021, mainly due to increased interest expenses from the Capella investment[26]. - The company incurred a fair value loss of HKD 92,579,000 on investments in an associate during the reporting period[127]. - Interest expenses increased to HKD 3,874,000 from HKD 1,978,000 year-over-year[158]. Assets and Liabilities - As of June 30, 2022, the group's cash and bank balances were HKD 50.9 million, compared to HKD 39.3 million as of December 31, 2021[31]. - As of June 30, 2022, the total bank and other borrowings amounted to HKD 381.9 million, a decrease from HKD 388.2 million as of December 31, 2021[32]. - The company's equity attributable to owners decreased to HKD 274,344 thousand as of June 30, 2022, from HKD 391,662 thousand as of December 31, 2021[111]. - Total liabilities as of June 30, 2022, amounted to HKD 303,076,000, indicating a need for financial resource management[123]. - The total assets of the company as of June 30, 2022, amounted to HKD 770,417,000, with liabilities totaling HKD 402,019,000[146][148]. Cash Flow and Financing - The company’s operating cash flow for the six months ended June 30, 2022, was a net outflow of HKD 3,436,000, a significant decrease from HKD 46,800,000 in the previous year[118]. - The financing activities generated a net cash inflow of HKD 19,878,000 in the first half of 2022, compared to a net outflow of HKD 67,157,000 in the same period of 2021[121]. - The company plans to renew existing borrowings of HKD 302,996,000, which are due for repayment in May 2023, with sufficient collateral in the form of investment properties valued at HKD 468,015,000[123]. Investments and Acquisitions - The investment in Chime Biologics Limited (CBL) was valued at HKD 156,928,000 as of June 30, 2022, down from HKD 249,507,000 as of December 31, 2021, indicating a significant decline in market conditions affecting similar companies[178]. - The group is actively seeking investment targets within the CDMO value chain, including cell line development and culture medium formulation[53]. - The company is in the process of acquiring VMS Auto Italia Fin Services Holdings Limited, incurring legal and professional fees related to the acquisition[155]. Corporate Governance and Compliance - The company maintained compliance with the corporate governance code during the six months ending June 30, 2022, except for a deviation regarding the separation of roles between the chairman and CEO[84]. - The audit committee reviewed the unaudited condensed consolidated financial statements for the six months ending June 30, 2022[94]. - The company has adopted a standard code for directors' securities transactions, confirming compliance during the reporting period[85]. Share Capital and Dividends - The company did not declare an interim dividend for the six months ended June 30, 2022, consistent with the previous year[58]. - As of June 30, 2022, the company had a total issued share capital of 5,292,515,390 shares[69]. - The previous share option scheme adopted on May 28, 2012, expired on May 27, 2022, but options granted prior to its expiration remain valid[74].
意达利控股(00720) - 2022 - 中期财报